NCT05509361View on ClinicalTrials.gov

Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

950

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

November 24, 2023

Study Completion Date

November 24, 2023

Conditions
Plaque Psoriasis
Interventions
BIOLOGICAL

AK101 injection SC

AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.

Trial Locations (1)

Unknown

Peking university people's hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT05509361 - Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis | Biotech Hunter | Biotech Hunter